ClinicalTrials.gg
RecruitingNCT06683092Updated Nov 3, 2025

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

An observational study in Cystic Fibrosis, sponsored by Boston Children's Hospital. Recruiting at 18 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-11-03.

Sponsored by Boston Children's Hospital · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
200
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Cystic Fibrosis by Boston Children's Hospital — 1 open to participants now, 1 under way, none of them phase 3. Cystic Fibrosis · Boston Children's Hospital.

Started
2025
with 1 other
Observational
8 of 16
1 open now
Registered
15th of 16
by date

Among the 16 studies in Cystic Fibrosis by Boston Children's Hospital, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 15th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

1 of the 16 studies in Cystic Fibrosis by Boston Children's Hospital is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Cystic Fibrosis by Boston Children's Hospital, or all of them as a file.
02

Study summary

RETRIAL is a multi-site observational study of people with Cystic Fibrosis (PWCF) ages 6 and up starting the new triple-therapy modulator (vanzacaftor/tezacaftor/deutivacaftor (VTD)), after having experienced neuropsychiatric events and/or liver injury while taking elexacaftor/tezacaftor/ivacaftor (ETI) that resulted in a modification or discontinuation of standard ETI dosing.

Read the detailed description

RETRIAL is a prospective, longitudinal, observational, multi-site study of people with Cystic Fibrosis (PWCF) ages 6 and up who had to either change how they took or stop taking elexacaftor/tezacaftor/ivacaftor (ETI) due to new or worsening mental health/cognitive symptoms (such as depression, anxiety, mood, sleep, and/or brain fog/memory problems) and/or liver issues (elevated liver enzymes) while taking the standard dose, and who plan to start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • patient care
  • adverse events
  • monitoring
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Female and male people with CF ages 6 and older who are not able to tolerate the standard dose of ETI due to either new/worsening mental health symptoms and/or drug-induced liver injury.

Eligibility criteria

Inclusion Criteria:

RETRIAL-Mental Health:

  • PWCF age 6 years and up (if age is \< 12 years old, the PWCF's caregiver will complete daily diaries and surveys; see "Caregiver Participant Inclusion Criteria" below)
  • Eligible for VTD and intending to take it
  • Experienced new or worsening mental health symptoms after initiating ETI, which led to one of the following changes in treatment to currently taking:

    1. No modulators
    2. A modulator other than ETI
    3. A flipped dose of ETI
    4. A reduced dose of ETI
  • Willing to delay first VTD dose for short period of time to complete the Baseline assessments
  • Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links
  • Is English-speaking.

RETRIAL-LIVER:

  • A person with CF age 6 years and up
  • Eligible for VTD and intending to take it
  • Experienced drug-induced liver injury (as defined by local care team) after initiating ETI, which led to one of the following changes in treatment to currently taking:

    1. no modulators; or
    2. a modulator other than ETI; or
    3. a reduced or altered dose of ETI;
  • Willing to delay first VTD dose for short period of time to complete the Baseline assessments
  • Has access to a smart device (phone, tablet, etc.) capable of receiving messages with survey links
  • Is English-speaking.

Exclusion Criteria:

RETRIAL-Mental Health:

  • Cannot access VTD
  • Currently, or prior history of, taking VTD
  • Unable or unwilling to follow protocol
  • If \<12 years old, having another \<12-year-old person in the same household consented into the study
  • Is actively listed on any transplant list, or within 3 months post-transplant surgery
  • Is currently pregnant (test not required)
  • Anticipated change in CF Care Centers in the next 6 months
  • Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

RETRIAL-LIVER:

  • Cannot access VTD
  • Currently, or prior history of, taking VTD
  • Unable or unwilling to follow protocol
  • If \<12 years old, having another \<12-year-old person in the same household consented into the study
  • Any severe, decompensated liver disease (e.g. , Class C)
  • Is actively listed on any transplant list, or within 3 months post-transplant surgery (any organ), or history of liver transplant
  • Is currently pregnant (test not required)
  • Anticipated change in CF Care Centers in the next 6 months
  • Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

Caregiver Participant:

Inclusion Criteria:

  • Is a primary, daily caregiver of a person with CF under the age of 12 enrolled in the study
  • Has access to smart device (phone, tablet, etc.) capable of receiving messages with survey links
  • Is able to read and complete surveys and Daily Diary in English.

Exclusion Criteria:

- Any situation that, in the opinion of the Investigator, would compromise the safety of the patient or the quality of the data.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • RETRIAL-Mental Health

    People with CF ages 6 and up with a history of new or worsening mental health symptoms (such as depression, anxiety, mood, sleep) while on elexacaftor/tezacaftor/ivacaftor (ETI) requiring discontinuation or change from standard dosing who start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).

    Other: RETRIAL-Mental Health

  • RETRIAL-Neuro

    People with CF from RETRIAL-Mental Health who experienced new/worsening neurocognitive symptoms (such as brain fog or memory problems) while taking elexacaftor/tezacaftor/ivacaftor (ETI).

    Other: RETRIAL-Neuro

  • RETRIAL-Liver

    People with Cystic Fibrosis ages 6 and up with a history of drug-induced liver injury (such as elevated liver enzymes) attributed to elexacaftor/tezacaftor/ivacaftor (ETI) requiring dose modification or discontinuation who start taking vanzacaftor/tezacaftor/deutivacaftor (VTD).

    Other: RETRIAL-Liver

Interventions

  • OtherRETRIAL-Mental Health

    Participants will complete: daily diaries for 6 weeks, from about 2 weeks prior to starting VTD to about 4 weeks after; biweekly surveys, from about 2 weeks prior to starting VTD to 6 months after, and 2 quarterly surveys (at 9mo and 12mo post-initiation of VTD).

  • OtherRETRIAL-Liver

    Participants may have a research liver function test done prior to starting VTD and 28 days after, if not done clinically. Participants will complete surveys: before starting VTD, a month after, and quarterly (at about 3, 6, 9, and 12 months) following VTD initiation.

  • OtherRETRIAL-Neuro

    Participants will complete a neurocognitive assessment prior to starting VTD and 28 days after.

06

What researchers measure

Primary outcomes

  1. RETRIAL-Mental Health (1st objective - discontinuation): one-year incidence of discontinuation or change from VTD standard dosing due to new/worsening mental health symptoms.

    Discontinuation or change from VTD standard dosing due to mental health symptoms at any time during the one-year follow-up as reported in either: daily diaries, biweekly or quarterly surveys, or chart review.

    Time frame: Baseline to Month 12

  2. RETRIAL-Mental Health (2nd objective - symptoms): proportion of participants that experience any worsening in mental health symptoms during the 6-month follow-up

    Change from baseline that exceeds the minimally-important difference (MID) / minimally-important change (MIC) within the first 6 months after starting VTD in any of the following patient-reported outcome measures: (1) depression (PHQ-8 or PROMIS depression parent proxy), (2) anxiety (GAD-7 or PROMIS anxiety parent proxy), (3) anger and irritability (PROMIS-anger or PROMIS-anger parent proxy), (4) cognitive functioning (PROMIS- cognitive function or PROMIS-cognitive function parent proxy), (5) sleep disturbance (PROMIS-sleep disturbance or PROMIS-sleep disturbance parent proxy).

    Time frame: Baseline to Month 6

  3. RETRIAL-Mental Health (3rd objective - RETRIAL-Neuro): proportion of participants that have a worsening on the NIH Toolbox's Fluid Cognition Composite score at 1 month follow-up.

    Decrease in age-adjusted standard score from baseline to 1 month on the NIH Toolbox's Fluid Cognition Composite Score (a performance-based neurocognitive measure) that exceeds MIC ≥ 7.5 points, signifying a worsening in function.

    Time frame: Baseline to Day 30

  4. RETRIAL-Liver: one-year incidence of drug-induced liver injury (DILI) with VTD, defined by expert consensus after review of clinical and laboratory data.

    Positive DILI diagnosis, including those characterized as "likely," "probable," and "highly probable," as reviewed by a hepatology panel of three experts who assign these likelihood scores based upon review of case report forms, including a specific clinical narrative and laboratory values assessing for other potential etiologies.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. RETRIAL-Mental Health (1st objective - discontinuation): one-year incidence of discontinuation or change from VTD standard dosing due to any reason.

    Reported discontinuation or change from VTD standard dosing due to any reason during the one-year follow-up as reported in either: daily diaries, biweekly or quarterly surveys, or chart review.

    Time frame: Baseline to Month 12

  2. RETRIAL-Mental Health (2nd objective - symptoms): proportion of participants that experience worsening of _each_ mental health symptom during the 6-month follow-up.

    Change from baseline that exceeds the MID/MIC of new/worsening symptoms within the first 6 months after starting VTD for \_each\_ of the following patient-reported outcomes: (1) depression (PHQ-8 or PROMIS depression parent proxy), (2) anxiety (GAD-7 or PROMIS anxiety parent proxy), (3) anger and irritability (PROMIS-anger or PROMIS-anger parent proxy), (4) cognitive functioning (PROMIS- cognitive function or PROMIS-cognitive function parent proxy), (5) sleep disturbance (PROMIS-sleep disturbance or PROMIS-sleep disturbance parent proxy).

    Time frame: Baseline to Month 6

  3. RETRIAL-Mental Health (3rd objective - RETRIAL-Neuro): proportion of participants that have a worsening of _each_ of the NIH Toolbox's cognition domain score at 1 month follow-up.

    Decrease in age-adjusted standard score from baseline to 1-month that exceeds MIC ≥ 7.5 points for \_each\_ of the following domains: (1) Flanker, (2) Dimensional Change Card Sort (DCCS), (3) Picture Sequence Memory Test (PSMT), (4) List Sorting, (5) Pattern Comparison.

    Time frame: Baseline to Month 1

  4. RETRIAL-Liver: one-year incidence of discontinuation or change from VTD standard dosing due to patient-reported or medical team-documented concerns for liver injury.

    Reported discontinuation or change from VTD standard dosing due to concerns for liver injury during the one-year follow-up as reported in either: 28-day or quarterly surveys, chart review, or case report forms.

    Time frame: Baseline to Month 12

07

Study locations

16 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Mar 2028, 34 months after the start.

Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's planned 34 months is below that.

Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2024
First posted
Nov 12, 2024
StartActual
May 1, 2025
Primary completionEst.
Mar 2028
CompletionEst.
Jun 2028
Last update
Nov 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06683092
Responsible party
Gregory Sawicki (Co-Chair of Success with Therapies Research Consortium, Boston Children's Hospital) — Principal investigator
First posted
Nov 12, 2024
Start date
May 1, 2025
Primary completion
Mar 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 3, 2025

Study contacts

Evelyn Bord, BS
Contact
evelyn.bord@childrens.harvard.edu
617-919-6154
Callie Bacon, MPH
Contact
callie.bacon@childrens.harvard.edu
617-919-7696
Anna Georgiopoulos, MD
principal investigator · Massachusetts General Hospital
CJ Bathgate, PhD
principal investigator · National Jewish Health
Janis Stoll, MD
principal investigator · Washington University at St. Louis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion